Tuberous Sclerosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
Who is this for?
Show terms as
2FDA treatments3Active trials5Specialists8Treatment centers3Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Tuberous Sclerosis is treated with 1 medication in our database, including HYFTOR. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Nobelpharma. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Tuberous Sclerosis treatment below.

Also known as:

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

NORD ↗

FDA & Trial Timeline

3 events
Jan 2023Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex

Katarzyna Kotulska — PHASE3

TrialRECRUITING
Jan 2022Gait in Rare Diseases

Universiteit Antwerpen — NA

TrialACTIVE NOT RECRUITING
Jan 2000Study of Skin Tumors in Tuberous Sclerosis

National Heart, Lung, and Blood Institute (NHLBI) — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Crestor

rosuvastatin· iPR Pharmaceuticals, Inc.

As an adjunct to diet to reduce LDL-C and slow the progression of atherosclerosis in adults

HYFTOR

sirolimus· Nobelpharma

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo

Clinical Trials

3 recruitingView all trials with filters →
Phase 31 trial
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
Phase 3
Actively Recruiting
· Sites: Lodz; Warsaw · Age: 050 yrs
N/A2 trials
Gait in Rare Diseases
N/A
Active
PI: Anna Jansen, MD, PhD (University Hospital, Antwerp) · Sites: Antwerp · Age: 625 yrs
Study of Skin Tumors in Tuberous Sclerosis
N/A
Actively Recruiting
PI: Joel Moss, M.D. (National Heart, Lung, and Blood Institute (NHLBI)) · Sites: Bethesda, Maryland · Age: 1890 yrs

Specialists

5 foundView all specialists →
DP
Darcy A Krueger, MD, PhD
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 1 active trial
MM
Mary Kay Koenig, MD
Houston, Texas
Specialist

Rare Disease Specialist

PI on 4 active trials
JM
Joel Moss, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 11 active trials
KM
Kim E. Nichols, MD
Memphis, Tennessee
Specialist

Rare Disease Specialist

PI on 2 active trials
AP
Anna Jansen, MD, PhD
Silver Spring, Maryland
Specialist

Rare Disease Specialist

PI on 2 active trials

Treatment Centers

8 centers
⚗️ Trial Site

National Institutes of Health Clinical Center

📍 Bethesda, Maryland

👤 Payal P Khincha, M.D.

👤 Christopher Grunseich, M.D.

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

Financial Resources

1 resources
Crestor(rosuvastatin)iPR Pharmaceuticals, Inc.

2 travel grants are also available for Tuberous Sclerosis patients — see Travel Grants below ↓

Travel Grants

2 grants

Afinitor Everolimus Copay Assistance Program

Eligibility requires a valid prescription for an approved indication and varies by program, with copay cards for commercially insured patients and foundation assistance for those with limited income or no insurance. Applicants must be U.S. residents and typically 18 years or older to qualify for financial support.

Apply ↗

Tuberous Sclerosis Association Support Fund

Tuberous Sclerosis Association

Apply ↗

Community

Open Tuberous SclerosisForum →

No community posts yet. Be the first to share your experience with Tuberous Sclerosis.

Start the conversation →

Latest news about Tuberous Sclerosis

Disease timeline:

New trial: Gait in Rare Diseases

Phase NA trial recruiting.

New trial: Study of Skin Tumors in Tuberous Sclerosis

Phase NA trial recruiting.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Tuberous Sclerosis

What is Tuberous Sclerosis?

Tuberous Sclerosis is treated with 1 medication in our database, including HYFTOR. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Nobelpharma. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Tuberous Sclerosis treatment below.

How is Tuberous Sclerosis inherited?

Tuberous Sclerosis follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Tuberous Sclerosis?

Yes — 3 recruiting clinical trials are currently listed for Tuberous Sclerosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Tuberous Sclerosis?

5 specialists and care centers treating Tuberous Sclerosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Tuberous Sclerosis?

1 FDA-approved treatment are currently tracked on UniteRare for Tuberous Sclerosis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.